Futurama: Psychedelics w/ Ronan Levy of Field Trip Health (CSE:FTRP)
Welcome to new subscribers! At Futurama, we dissect emerging industries and breakthrough technologies that solve meaningful problems and have the potential to change the way we live. We deliver a monthly issue and bi-weekly podcast episodes, keeping you ahead of the curve with a thoughtful analysis, compiled from +100 hours of research and interviews with leading scientists, investors, and the most ambitious entrepreneurs.
Ronan Levy is the co-founder and CEO of Field Trip Health (CSE:FTRP), a company addressing mental health disorders by developing psychedelic compounds and building out a network of treatment clinics that offer psychedelic-assisted therapies. Concurrent with his work at Field Trip, he is a partner at Grassfed Ventures, a venture capital firm focused on the cannabis and biotech industries, and is Chief Strategy Officer and Member of the Board of Directors for Trait Biosciences Inc., a leading biotech company in the hemp and cannabis industries. He is also a pioneer in the medical cannabis industry, having co-founded Canadian Cannabis Clinics and CanvasRx Inc., the latter of which was acquired by Aurora Cannabis Inc. (NYSE:ACB) in 2016, after which he served as Senior Vice President, Business and Corporate Affairs for Aurora. A lawyer by training, Ronan started his career as a corporate lawyer at Blake, Cassels Graydon LLP, and Legal Counsel at CTVglobemedia Inc. (now Bell Media Inc.) He holds a Juris Doctor and a Bachelor of Commerce degree, both from the University of Toronto.
A Snapshot: Field Trip Health
Founding Date: 2019
HQ: Toronto, Canada
Founders: Mujeeb Jafferi, Ryan Yermus, Joseph del Moral, Ronan Levy, Hannan Fleiman
Funding Raised: $20M
Notable Investors: What If Ventures, Subversive Capital, Bolt, etc.
Stage: IPO (CSE)
Substances: Ketamine, Psilocybin, FT-105, with more to come...
Founded in 2019 by cannabis entrepreneurs and based out of Toronto, Field Trip addresses mental health disorders by establishing treatment clinics offering psychedelic-assisted therapy across the United States, Canada, and the Netherlands. In addition, it aims to conduct its own drug development and drug manufacturing based on a wide range of psychedelic compounds such as psilocybin, for which it has partnered with the University of the West Indies in Jamaica, and its proprietary novel psychedelic molecule FT-105 with which it aims to launch clinical trials at the end of 2021. For now, Field Trip operates three psychotherapy clinics in Toronto, Los Angeles, Chicago, and New York through which it offers ketamine-assisted therapy sessions to treat anxiety and depression as it is the only legal psychedelic approved by the FDA. Eventually, they aim to move beyond ketamine and scale up to over 75 treatment clinics as certain compounds gain FDA approval or become legal such as the legalization of psilocybin in the state of Oregon.
Breakthroughs:
March 2020: Field Trip opens the first-of-its-kind psychedelic-enhanced psychotherapy clinic in Toronto, Canada.
April 2020: Field Trip spins-out its drug discovery arm “Field Trip Discovery”.
July 2020: Field Trip launches Basecamp, a therapeutic program for combat veterans, first responders, and healthcare workers.
October 2020: Field Trip gets publicly listed and commences trading on the CSE.
November 2020: Field Trip expands to the Netherlands, aiming to provide psychedelic-assisted therapy with legal truffles containing psilocybin at a Field Trip Health Center in Amsterdam.
November 2020: Field Trip prepares its expansion into the Oregon market, following the legalization of psilocybin in the state.
If you enjoy reading Futurama, do share it with one or two curious friends! If you want to stay ahead of the curve and keep an eye on the future, then subscribe above and unlock the future with our monthly Futurama and exclusive podcast episodes straight in your mailbox!
The Future Belongs to the Curious,
Neal & Lukas